Elutia CEO Says EluPro Success Transforms Company
"The success of EluPro was transformational for Elutia," said Dr. Randy Mills, Chief Executive Officer. "It validated the technical and commercial capability of our drug-eluting platform and enabled us to enter plastic and reconstructive surgery, where complication rates in breast reconstruction remain unacceptably high. We enter 2026 with a strong balance sheet and the capital required to develop and commercialize NXT-41x. With an experienced team and a focused strategy, we are positioned to execute and advance our mission so that patients can thrive without compromise."
Trade with 70% Backtested Accuracy
Analyst Views on ELUT
About ELUT
About the author
Elutia Regains Compliance with Nasdaq Listing Standards
- Compliance Restored: Elutia has successfully met Nasdaq's minimum bid price requirement, marking a significant advancement in compliance that enhances investor confidence and may attract more institutional investors.
- Market Value Met: The company also satisfied the minimum market value of listed securities requirement, ensuring its continued listing on Nasdaq, which could enhance its market image and brand value.
- Stock Price Surge: Following the restoration of compliance, Elutia's shares rose 6.5% in premarket trading, reflecting optimistic market sentiment towards the company's prospects and potentially supporting future financing and expansion efforts.
- Sales Outlook: Elutia anticipates Q4 net sales of $3.3 million, indicating stability and growth potential in the market, which may draw increased investor attention to its future performance.
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
Elutia Showcases NXT-41x Antibiotic-Eluting Biomatrix Technology
- Technological Advancement: Elutia will showcase its NXT-41x program at the Global BioInnovation Forum, aimed at addressing the postoperative infection complication rate of up to 25% in breast reconstruction, highlighting the potential of its biomatrix technology in clinical applications.
- Industry Demand: The development of this technology responds to the urgent needs in the breast reconstruction field, particularly given that one in three patients faces serious complications, underscoring Elutia's critical role in medical innovation.
- Leadership Team: CEO Randy Mills will present alongside Dr. Christopher Reid from UC San Diego Health, whose expertise in microsurgery and complex breast reconstruction will support the clinical application of the technology.
- Market Opportunity: Elutia's NXT-41x project builds on its validated biomatrix technology platform and aims to drive growth in the rapidly evolving medical device market by addressing unmet clinical needs.
After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience
Kura Oncology's Gains: Kura Oncology's shares rose 7.42% in after-hours trading, likely due to positive investor reactions to data from its KOMET-007 trial for acute myeloid leukemia.
SOPHiA GENETICS Collaboration: SOPHiA GENETICS saw a 5.21% increase in share price, attributed to ongoing interest in its collaboration with Complete Genomics for precision oncology testing.
Elutia and RenovoRx Performance: Elutia Inc. and RenovoRx, Inc. experienced modest gains, with Elutia up 3.10% and RenovoRx up 2.47%, reflecting steady investor interest in the biotech sector.
Kodiak Sciences and Other Companies: Kodiak Sciences gained 5.42% following a successful public offering, while Day One Biopharmaceuticals and Quantum BioPharma also saw increases, indicating a broader positive trend in biotech stocks.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Elutia Welcomes Experienced MedTech Leader Guido J. Neels to Its Board of Directors
New Board Appointment: Elutia Inc. has appointed Guido J. Neels to its Board of Directors, who will also serve on the audit committee, following the resignation of W. Matthew Zuga and Maybelle Jordan from the board.
Guido Neels' Background: Neels brings over 40 years of experience in the medical technology sector, having held significant roles at EW Healthcare Partners and Guidant Corporation, and is expected to contribute valuable insights as Elutia focuses on enhancing shareholder value through its drug-eluting biomatrix technology.
Elutia Regains Compliance with Nasdaq Listing Standards
- Compliance Restored: Elutia has successfully met Nasdaq's minimum bid price requirement, marking a significant advancement in compliance that enhances investor confidence and may attract more institutional investors.
- Market Value Met: The company also satisfied the minimum market value of listed securities requirement, ensuring its continued listing on Nasdaq, which could enhance its market image and brand value.
- Stock Price Surge: Following the restoration of compliance, Elutia's shares rose 6.5% in premarket trading, reflecting optimistic market sentiment towards the company's prospects and potentially supporting future financing and expansion efforts.
- Sales Outlook: Elutia anticipates Q4 net sales of $3.3 million, indicating stability and growth potential in the market, which may draw increased investor attention to its future performance.
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
Elutia Showcases NXT-41x Antibiotic-Eluting Biomatrix Technology
- Technological Advancement: Elutia will showcase its NXT-41x program at the Global BioInnovation Forum, aimed at addressing the postoperative infection complication rate of up to 25% in breast reconstruction, highlighting the potential of its biomatrix technology in clinical applications.
- Industry Demand: The development of this technology responds to the urgent needs in the breast reconstruction field, particularly given that one in three patients faces serious complications, underscoring Elutia's critical role in medical innovation.
- Leadership Team: CEO Randy Mills will present alongside Dr. Christopher Reid from UC San Diego Health, whose expertise in microsurgery and complex breast reconstruction will support the clinical application of the technology.
- Market Opportunity: Elutia's NXT-41x project builds on its validated biomatrix technology platform and aims to drive growth in the rapidly evolving medical device market by addressing unmet clinical needs.
After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience
Kura Oncology's Gains: Kura Oncology's shares rose 7.42% in after-hours trading, likely due to positive investor reactions to data from its KOMET-007 trial for acute myeloid leukemia.
SOPHiA GENETICS Collaboration: SOPHiA GENETICS saw a 5.21% increase in share price, attributed to ongoing interest in its collaboration with Complete Genomics for precision oncology testing.
Elutia and RenovoRx Performance: Elutia Inc. and RenovoRx, Inc. experienced modest gains, with Elutia up 3.10% and RenovoRx up 2.47%, reflecting steady investor interest in the biotech sector.
Kodiak Sciences and Other Companies: Kodiak Sciences gained 5.42% following a successful public offering, while Day One Biopharmaceuticals and Quantum BioPharma also saw increases, indicating a broader positive trend in biotech stocks.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Elutia Welcomes Experienced MedTech Leader Guido J. Neels to Its Board of Directors
New Board Appointment: Elutia Inc. has appointed Guido J. Neels to its Board of Directors, who will also serve on the audit committee, following the resignation of W. Matthew Zuga and Maybelle Jordan from the board.
Guido Neels' Background: Neels brings over 40 years of experience in the medical technology sector, having held significant roles at EW Healthcare Partners and Guidant Corporation, and is expected to contribute valuable insights as Elutia focuses on enhancing shareholder value through its drug-eluting biomatrix technology.
